Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
The chiplets design combines IP access, interposer expertise, and relationships with HBM suppliers, foundries and OSATs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results